Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical or view top-rated stocks.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest in April. As of April 15th, there was short interest totaling 5,910,000 shares, an increase of 32.8% from the March 31st total of 4,450,000 shares. Based on an average daily volume of 2,580,000 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the company's shares are short sold.
View Takeda Pharmaceutical's Short Interest.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for Takeda Pharmaceutical.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.66 per share and currently has a dividend yield of 4.48%. TAK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Takeda Pharmaceutical is 77.65%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2022 earnings guidance on Wednesday, May, 18th. The company provided EPS guidance of $3.99-$3.99 for the period. The company issued revenue guidance of $30.39 billion-$30.39 billion.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:

• Mr. Christophe Weber, Pres, CEO & Representative Director (Age 56, Pay $11.45M)
• Mr. Constantine Saroukos, CFO & Representative Director (Age 51, Pay $4.13M)
• Mr. Yasuhiko Yamanaka, Advisor (Age 66, Pay $290.97k)
• Dr. Andrew S. Plump, Pres of R&D and Representative Director (Age 57, Pay $5.89M)
• Dr. Seigo Izumo, Chair of Management Board
• Mr. Haruhiko Hirate, Member of Management Board (Age 65)
• Salvatore Alesci, Member of Management Board and Head of R&D Global Science & Biomedical Policy
• Norimasa Takeda, Chief Accounting Officer & Corp. Controller
• Mr. Iwaaki Taniguchi, Sr. VP of Corp. Fin. & Controlling Department
• Mr. Gabriele Ricci, Chief Data & Technology Officer

Who are some of Takeda Pharmaceutical's key competitors?

Some companies that are related to Takeda Pharmaceutical include Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), Astellas Pharma (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Genmab A/S (GMAB) and Genmab A/S (GNMSF).
View all of TAK's competitors.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mondrian Investment Partners LTD (0.14%), Goldman Sachs Group Inc. (0.13%), BlackRock Inc. (0.10%), Northern Trust Corp (0.07%), Brandes Investment Partners LP (0.07%) and Renaissance Technologies LLC (0.06%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Vanguard Group Inc., BNP Paribas Arbitrage SA, Northern Trust Corp, First Trust Advisors LP, Sei Investments Co., and Sawtooth Solutions LLC.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Brandes Investment Partners LP, Renaissance Technologies LLC, Mondrian Investment Partners LTD, Clean Yield Group, Natixis Advisors L.P., and Arrowstreet Capital Limited Partnership.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $14.72.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $46.58 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.849990 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 47,000 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.